<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Programmed <z:hpo ids='HP_0011420'>death</z:hpo> 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1) is a lymphoid receptor that negatively regulates immune responses </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 expression was recently reported in some T-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) subtypes, but the expression profile of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 and its ligands (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L2) in B-NHLs remains largely to be characterized </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate this issue, monoclonal antibodies against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L2 were generated by immunization of balb-c mice </plain></SENT>
<SENT sid="3" pm="."><plain>A series of 161 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> tissue and 11 blood samples was analyzed using either immunohistochemistry or flow cytometry </plain></SENT>
<SENT sid="4" pm="."><plain>In reactive lymph nodes, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 was mainly expressed in follicular T cells </plain></SENT>
<SENT sid="5" pm="."><plain>In B-NHLs, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 was mainly expressed in reactive T cells; but expression was also noted in neoplastic B cells from small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>, 12/13), grade III follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (3/3), and diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2/25) </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, neoplastic B cells from mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0/11), marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0/12), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0/3), and grade 1 to 2 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (0/40) were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 negative </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L2 were negative in small B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including B-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Flow cytometry showed that blood cells from <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (B-CLL) also displayed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 expression, which could be increased by CD40 stimulation </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 expression in T-NHLs was restricted to the angioimmunoblastic subtype (8/8) </plain></SENT>
<SENT sid="10" pm="."><plain>These results show that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 expression among B-NHLs is mainly associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL and is influenced by activation of the CD40/CD40L pathway </plain></SENT>
<SENT sid="11" pm="."><plain>Because the anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1.6.4 antibody works on paraffin sections, it represents a useful tool to differentiate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL from other small B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>